Merus saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 80 to 84.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's proprietary RS Rating identifies market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks matches up against the rest of the market.
Decades of market research shows that the market's biggest winners often have an RS Rating north of 80 in the early stages of their moves.
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock goes on to offer and clear an appropriate buy point.
Merus showed 0% EPS growth in its most recent report. Revenue rose 236%. Keep an eye out for the company's next round of numbers on or around Jul. 31.
The company holds the No. 124 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and ACADIA Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
